-
Mashup Score: 1Novo Nordisk’s obesity newcomer monlunabant heads into Phase IIb - 8 month(s) ago
Novo Nordisk has announced positive Phase IIa results for monlunabant, a small molecule oral CB1 inverse agonist for obesity. The trial showed significant weight loss with a 10 mg dose, achieving a 7.1 kg reduction versus 0.7 kg for placebo. Mild to moderate side effects were reported. A Phase IIb trial is planned for 2025
Source: www.thepharmaletter.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0Apellis and Sobi come unstuck in ALS - 2 year(s) ago
US biopharma Apellis Pharmaceuticals and Swedish Orphan Biovitrum, also known as Sobi, have become the latest to discover the difficulty of drug development in
Source: www.thepharmaletter.comCategories: Latest Headlines, Rare DiseaseTweet-
https://t.co/YchloTbGZe
-
-
Mashup Score: 3
Sanofi vWD therapy demonstrates significant potential of pipeline
Source: www.thepharmaletter.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Interesting story that Sanofi is looking to develop Altuviiio (BIVV-001, Efa) for use in 2N and type 3 von Willebrand disease. Altuviiio was recently approved for by the FDA for use in #hemophilia. #willebrand #VWD. https://t.co/WMxzGPOr4l
-
-
Mashup Score: 0uniQure licenses gene therapy from Apic Bio - 2 year(s) ago
uniQure licenses gene therapy from Apic Bio
Source: www.thepharmaletter.comCategories: Latest Headlines, Rare DiseaseTweet-
https://t.co/qQouD2FgfI
-
-
Mashup Score: 1
German pharma major Boehringer Ingelheim and US tech-based therapy firm Click Therapeutics have announced the launch of an expanded collaboration on a second pr
Source: www.thepharmaletter.comCategories: Future of Medicine, Latest HeadlinesTweet-
Boehringer punts up to $460 million on new Click app in schizophrenia https://t.co/eJvhD6zOy8 https://t.co/1sVrt4oeDF
-
-
Mashup Score: 0US FDA grants Fast Track status to BrainStorm Cell Therapeutics for ALS treatment NurOwn - 3 year(s) ago
The US Food and Drug Administration has designated a product from stem cell treatment developer BrainStorm Cell Therapeutics (Nasdaq: BCLI) as a Fast Track prod
Source: www.thepharmaletter.comCategories: Latest Headlines, Rare DiseaseTweet-
For those who have been questioning FDA Fast Track... https://t.co/eZl1OrC6eu It has been in place for 8 years. For most of the time since, the ball has been in the sponsor's court.
-
-
Mashup Score: 7
Indonesia’s PT BioFarma ready to produce IndoVac Covid-19 vaccine
Source: www.thepharmaletter.comCategories: Infectious Disease, Latest HeadlinesTweet-
Indonesia’s PT BioFarma ready to produce IndoVac Covid-19 vaccine More on the second version of our @TexasChildrens @BCM_TropMed Covid vaccine technology with @biofarmaID in Indonesia https://t.co/fykmpuUucC
-
-
Mashup Score: 5
FDA accepts efanesoctocog alfa BLA for priority review for people with hemophilia A
Source: www.thepharmaletter.comCategories: Hem/Oncs, Latest HeadlinesTweet-
The FDA has accepted BIVV001 or Efanesoctocog alfa (Efa) for priority review, with a decision date by the end of February 2023. This is the markedly extended half life FVIII which can be given once a week for prophylaxis. https://t.co/UBWsR21sGo #Hemophilia #Haemophilia #FVIII
-
-
Mashup Score: 0
The US Food and Drug Administration (FDA) has unveiled an Action Plan for Rare Neurodegenerative Diseases including Amyotrophic Lateral Sclerosis (ALS).
Source: www.thepharmaletter.comCategories: Latest Headlines, Rare DiseaseTweet-
Umm... They took "the bull by the horns" because a new law required the plan. We'll see... FDA takes the bull by the horns on rare neurodegenerative diseases https://t.co/sMKdGrrpvt
-
-
Mashup Score: 27
Biological E has place in India’s COVID-19 vaccine market following Corbevax’ approval
Source: www.thepharmaletter.comCategories: Healthcare Professionals, Latest HeadlinesTweet-
Biological E has place in India’s COVID-19 vaccine market following Co https://t.co/ZV9Hylwrme
-
RT @ThePharmaLetter: @novonordisk's obesity newcomer monlunabant heads into Phase IIb https://t.co/c3dOMdlgjZ